Notice NOT-HD-22-028 from the NIH Guide for Grants and Contracts

Notice NOT-NS-22-109 from the NIH Guide for Grants and Contracts

Notice NOT-NS-22-108 from the NIH Guide for Grants and Contracts

Notice NOT-NS-22-107 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-23-023 from the NIH Guide for Grants and Contracts. The accumulation of misfolded proteins in the brain is a key pathological feature shared by many neurodegenerative diseases that can result in dementia such as Alzheimers Disease, Lewy Body Diseases, Frontotemporal Degeneration, and cerebral amyloid angiopathy. Classical prion diseases such as Creutzfeldt-Jakob Disease are a rare family of neurodegenerative disorders that occur when the cellular prion protein (PrPC) undergoes structural conversion to a pathological form (PrPSc), which is usually triggered by its interaction with an infectious variant of the protein that forces the conformational change. Once this process is initiated, it becomes self-propagating until toxic aggregates accumulate within the CNS, leading to neuronal death. Because misfolded proteins of AD/ADRD have been reported to share some features with pathological prion protein at the structural level, it has thus been proposed that ADRD-relevant proteins such as Alpha, tau, beta-synuclein, and TDP-43 (among others) may exhibit prion-like behaviors that lead to toxic aggregate and tangle formation. The goal of this initiative is to promote studies that increase our understanding of the cellular and molecular mechanisms by which such prion-like conversion events occur and are propagated in AD/ADRD, as well as the downstream mechanisms that trigger neurotoxicity, pathological and circuit changes in the brain.

Notice NOT-NS-23-019 from the NIH Guide for Grants and Contracts

Notice NOT-OD-22-188 from the NIH Guide for Grants and Contracts

Notice NOT-HL-22-037 from the NIH Guide for Grants and Contracts

Notice NOT-HL-22-038 from the NIH Guide for Grants and Contracts

Notice NOT-MH-22-280 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-HD-23-013 from the NIH Guide for Grants and Contracts. This FOA invites applications to participate in a research program cooperative agreement to support the Prevention and Treatment through a Comprehensive Care Continuum for HIV-affected Adolescents in Resource Constrained Settings Implementation Science Network (PATC3H-IN). The Network will expand successes achieved by PATC3H to new geographic settings with limited implementation science (IS) research capacity and/or risk populations who are poorly represented in international adolescent HIV research (e.g. sexual and gender minorities; commercial sex workers; drug users) and stimulate much needed IS research in a neglected area of public health significance: prevention of new HIV infections among adolescents at risk and the identification of, and linkage and retention to care of and long-term viral suppression among youth living with HIV in low-to-middle income countries (LMICs). These settings must have an HIV epidemic density defined by UNAIDS estimates as either a country 1) in which at least 200,000 people are living with HIV and the number has not decreased by more than 5% over the last 2 consecutive years of available data or 2) has an HIV incidence among youth ages 10 to 24 years of 0.01% or more.

Funding Opportunity RFA-HD-23-014 from the NIH Guide for Grants and Contracts. This FOA invites applications to participate in a research program cooperative agreement to support the Prevention and Treatment through a Comprehensive Care Continuum for HIV-affected Adolescents in Resource Constrained Settings Implementation Science Network (PATC3H-IN). The Network will expand successes achieved by PATC3H to new geographic settings with limited implementation science (IS) research capacity and/or risk populations who are poorly represented in international adolescent HIV research (e.g. sexual and gender minorities; commercial sex workers; drug users) and stimulate much needed IS research in a neglected area of public health significance: prevention of new HIV infections among adolescents at risk and the identification of, and linkage and retention to care of and long-term viral suppression among youth living with HIV in low-to-middle income countries (LMICs). These settings must have an HIV epidemic density defined by UNAIDS estimates as either a country 1) in which at least 200,000 people are living with HIV and the number has not decreased by more than 5% over the last 2 consecutive years of available data or 2) has an HIV incidence among youth ages 10 to 24 years of 0.01% or more.

Funding Opportunity RFA-MH-22-240 from the NIH Guide for Grants and Contracts. The goal of this effort is to support the development and validation of next generation platforms and analytic approaches to precisely quantify behaviors in humans and link them with simultaneously recorded brain activity. Tools used for analyzing behavior should be multi-modal and should be able to be linked to brain activity and thus have the accuracy, specificity, temporal resolution, and flexibility commensurate with tools used to measure and modulate the brain circuits that give rise to those behaviors. This phased award will support novel tool development (i.e., hardware/software) in the R61 phase and synchronization of novel tools for measuring behavior and human brain activity in the R33 phase.

Funding Opportunity RFA-NS-23-004 from the NIH Guide for Grants and Contracts. The purpose of this Limited Competition Funding Opportunity Announcement is to allow Undiagnosed Diseases Network (UDN) Clinical Sites that received an NIH award under RFA-RM-17-019 an opportunity to compete for one additional year of NIH funding to: continue their participation in the UDN; establish collaborations and efficient processes with the next phase Data Management and Coordinating Center (DMCC; see: RFA-NS-22-051); enroll and evaluate new participants; and further develop their sustainability plans.

Notice NOT-HL-22-041 from the NIH Guide for Grants and Contracts

Notice NOT-OD-22-186 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DK-22-019 from the NIH Guide for Grants and Contracts. This U2C funding opportunity announcement (FOA) is a National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) initiative to establish a novel national Stakeholder Engagement Innovation Center for advancing equity in type 1 diabetes research (SEIC-T1D). A primary goal of the SEIC-T1D is to accelerate equitable engagement of diverse stakeholders in T1D research, particularly those from diverse communities that experience diabetes-related health disparities, as well as the healthcare and social systems that impact community members and patients health. The SEIC-T1D will provide highly specialized research resources to support investigators by fully embedding communities, people living with T1D, and other stakeholders into the full spectrum of research activities through expert consultations and education in principles and methods of community-engaged research. The SEIC-T1D will also establish a network consisting of diverse, multidisciplinary research investigators with expertise in T1D and community-engaged methods, community experts with lived experiences, and representatives of various health and other organizations deemed essential for addressing disparities and advancing health equity in T1D early detection and treatment.

Notice NOT-CA-22-108 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DK-22-503 from the NIH Guide for Grants and Contracts. The purpose of this Limited Competition is to extend the Chronic Renal Insufficiency Cohort (CRIC) Study by continuing to support the Scientific and Data Coordinating Center (SDCC). The CRIC Study is a multi-center, prospective, observational cohort study of men and women with chronic kidney disease (CKD). The CRIC Clinical Centers will complete follow-up previously enrolled participants under a separate FOA with a focus on completing enrollment into ongoing sub-studies that utilize at-home assessments of kidney and cardiovascular function. The primary objective of this FOA is to support the SDCC to lead the study group to achieve the scientific goals of the next project period and develop a sustainable strategy to disseminate the CRIC data and samples to the larger research community, as well as ensure that all study samples and data are archived into the NIDDK Central Repository.

Funding Opportunity RFA-NS-22-055 from the NIH Guide for Grants and Contracts. This FOA invites applications that propose the comprehensive functional validation of newly identified therapeutic target candidates for Alzheimer's Disease-Related Dementias (ADRDs). This FOA seeks to promote critical target validation approaches to help de-risk subsequent translational research and accelerate the advancement of novel therapies for ADRD. Target(s) or molecular pathway(s) to be considered for validation must have been already identified using tissue expression or genetic data generated in human samples. In its initial phase, this FOA provided support for up to two years (R61 stage) for the development of customized technologies, models, and protocols to modulate the expression or activity of target candidate(s) in cells or tissues and monitor their functional biological consequences in in vitro or in vivo disease models. Upon demonstration of technical feasibilities, a second phase (R33 stage) will carefully and reproducibly measure and cross-validate the impact of the target modulation in different modalities across collaborating laboratories using the NIH rigor and reproducibility guidelines. Applicants responding to this FOA must address objectives for both the UG3 and UH3 phases and are expected to have a substantial collaborative effort between independents laboratories. This FOA is not specific for any one or group within the ADRD spectrum of disorders. Disorders covered in these applications are frontotemporal degeneration (FTD), Lewy body dementias (LBD) (including dementia with Lewy bodies (DLB)), Parkinson disease dementia (PDD), vascular contributions to cognitive impairment and dementia (VCID), mixed dementias including the associated diagnostic challenges of multiples etiology dementias (MED).